Answers are grounded in this paper and cite their sources.
Reports initial findings up to 48 months in early Alzheimer's disease, suggesting potential long-term benefits of treatment.
To report the initial findings up to 48 months from the ongoing Clarity AD open-label extension (OLE) study.
No takes yet. Share an insight, caveat, or question.
Dyck et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: